" The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) allows the conversation about hormone therapy for menopausal women to be individualized for a specific woman. Instead of the recommendation of "lowest dose for the shortest period of time," the NAMS Hormone Therapy Position Statement Advisory Panel's review of the literature on hormone therapy suggests that women are better served using evidence-based information to determine the most appropriate type, dose, formulation, route of administration, and duration of use of hormone therapy. Decisions about hormone therapy should be based on the unique health risks of the woman, age or time from menopause, and goals of therapy."
This is a direct quote from the first paragraph of the perspective publication titled Changing the Conversation About Hormone Therapy written by JoAnn V. Pinkerton, MD, NCMP in the journal Menopause. (2017;24(9):991-993).
Finally women are getting information based on the multitude of studies available beyond the Women's Health Initiative (WHI) that began the fear mongering attitude surrounding hormones. I think the position paper continues to ignore a key factor in hormone replacement: the balance between estrogen and progesterone, which is equally important for women with or without an uterus. When the scientific literature is explored on that critical aspect of hormone replacement, I will be cheering even louder.
1.The 2017 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2017; 24:728–753.
2. NAMS Patient Handout
3. Changing the Conversation About Hormone Therapy. Menopause 2017;24(9):991-993.